Papers/PMID:36453265
Post-diagnostic Zinc Supplement Use and Prostate Cancer Survival Among Men With Nonmetastatic Prostate Cancer.
The Journal of urology2023The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
Zn(2+) — decreases all-cause mortality
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×4“Compared to non-users, post-diagnosis zinc supplement use was associated with a suggestively lower risk of lethal prostate cancer (HR [95% CI], 0.82 [0.60–1.13]) and significantly lower all-cause mortality (0.84 [0.74–0.96]).”
Quoted verbatim from Post-diagnostic Zinc Supplement Use and Prostate Cancer Survival Among Men With Nonmetastatic Prostate Cancer.. - Study
- cohort
- Dose
- any post-diagnostic zinc supplement use (self-reported; dose categories <25 to >=101 mg/day)
- Population
- Men with nonmetastatic prostate cancer in the Health Professionals Follow-up Study (5,788 men; 851 reported post-diagnosis zinc supplement use), compared with non-users; median follow-up 11 years
Effect 0.84 hazard ratio, 95% CI 0.74 to 0.96
Post-diagnostic Zinc Supplement Use and Prostate Cancer Survival Among Men With Nonmetastatic Prostate Cancer.2023PMID:36453265Permalink